
Professor Robert Hills
Honorary Professor
- Email:
- hillsrk@cardiff.ac.uk
- Telephone:
- +44 (0)29 2074 4647
- Media commentator
I am a translational statistician working in the integration of clinical trials and laboratory studies. My main area of expertise is Acute Myeloid Leukaemia where I am statistician and grantholder for the UK NCRI portfolio of randomised trials.
The UK NCRI trials are the largest in the world, and have pioneered the use both of molecular screening to identify different types of patient to receive different types of therapy, but also the use of sophisticated minimal residual disease assays to guide therapy. Through innovative designs such as multiple factorial randomisations, and Pick-A-Winner approaches, since 1988 some 20,000 patients have contributed over 40,000 randomisations to answer 60 questions.
Additionally, the NCRI AML Trials give rise to a large tissue bank of well-characterised samples, and this gives rise to numerous translational projects wit hthe aim of identifying novel targets for treatment.
At present I am also involved with applying these novel designs to other conditions, notably within cancer, and developing new trial designs to address the increasing statistical challenge of personalised medicine.
2018
- Burnett, A. K.et al. 2018. Addition of the mammalian target of rapamycin inhibitor, Everolimus, to consolidation therapy in acute myeloid leukaemia: experience from the UK NCRI AML17 trial. Haematologica 103(10), pp. 1654-1661. (10.3324/haematol.2018.189514)
- Russell, N.et al. 2018. Attenuated arsenic trioxide plus ATRA therapy for newly diagnosed and relapsed APL: long-term follow-up of the AML17 trial. Blood 132(13), pp. 1452-1454. (10.1182/blood-2018-05-851824)
- Marquis, M.et al. 2018. High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemia. Blood Cancer Journal 8(68) (10.1038/s41408-018-0103-6)
- Burnett, A. K.et al. 2018. A comparison of FLAG-Ida and daunorubicin combined with clofarabine in high-risk acute myeloid leukaemia: data from the UK NCRI AML17 Trial. Leukemia (10.1038/s41375-018-0148-3)
- Lucas, C. M.et al. 2018. CIP2A- and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML. Blood Advances 2(9), pp. 964. (10.1182/bloodadvances.2017013615)
- Parkinson, C.et al. 2018. Evaluation of prognostic models developed using standardised image features from different PET automated segmentation methods. EJNMMI Research 8, article number: 29. (10.1186/s13550-018-0379-3)
- Rajendram, R.et al. 2018. Combined immunosuppression and radiotherapy in thyroid eye disease (CIRTED): a multicentre, 2 × 2 factorial, double-blind, randomised controlled trial. Lancet Diabetes and Endocrinology 6(4), pp. 299-309. (10.1016/S2213-8587(18)30021-4)
- Gale, R. E.et al. 2018. No evidence that CD33 splicing SNP impacts the response to GO in younger adults with AML treated on UK MRC/NCRI trials. Blood 131(4), pp. 468-471. (10.1182/blood-2017-08-802157)
- Foley, K.et al. 2018. Development and validation of a prognostic model incorporating texture analysis derived from standardised segmentation of pet in patients with oesophageal cancer. European Radiology 28(1), pp. 428-436. (10.1007/s00330-017-4973-y)
2017
- Scurr, M.et al. 2017. Effect of modified vaccinia Ankara–5T4 and low-dose cyclophosphamide on antitumor immunity in metastatic colorectal cancer A Randomized Clinical Trial. JAMA Oncology 3(10), article number: e172579. (10.1001/jamaoncol.2017.2579)
- Scurr, M. J.et al. 2017. Low-dose cyclophosphamide induces anti-tumor T-cell responses which associate with survival in metastatic colorectal cancer. Clinical Cancer Research, article number: clincanres.0895.2017. (10.1158/1078-0432.CCR-17-0895)
- Hyatt, S.et al. 2017. Telomere length is a critical determinant for survival in multiple myeloma. British Journal of Haematology 178(1), pp. 94-98. (10.1111/bjh.14643)
- Williams, J.et al. 2017. Telomere length is an independent prognostic marker in MDS but not in de novo AML. British Journal of Haematology 178(2), pp. 240-249.
- Rice, C.et al. 2017. Structural and functional analysis of the human POT1-TPP1 telomeric complex. Nature Communications 8, article number: 14928. (10.1038/ncomms14928)
- Knapper, S.et al. 2017. A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML. Blood 129(9), pp. 1143-1154. (10.1182/blood-2016-07-730648)
- Hills, R. K. 2017. Non-inferiority trials: no better? no worse? no change? no pain?. British Journal of Haematology 176(6), pp. 883-887. (10.1111/bjh.14504)
- Burnett, A. K.et al. 2017. A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia. Leukemia 31(2), pp. 310-317. (10.1038/leu.2016.225)
- Hills, R. K. 2017. Statistical reporting in the BJH: some dos and don'ts. British Journal of Haematology 176(3), pp. 345-351. (10.1111/bjh.14426)
- Chilton, L.et al. 2017. Clinical relevance of failed and missing cytogenetic analysis in acute myeloid leukaemia. Leukemia 31(5), pp. 1234-1237. (10.1038/leu.2017.37)
- Scurr, M.et al. 2017. MVA-5T4 immunotherapy (TroVax) and low-dose cyclophosphamide for advanced colorectal cancer (TaCTiCC): an open-label, randomized phase 1/2 clinical trial. JAMA Oncology
2016
- Hills, R. K. 2016. Treatment intensification in diffuse large B-Cell lymphoma: lessons for clinical trial design. British Journal of Haematology 175(4), pp. 555-556. (10.1111/bjh.14400)
- Khan, N.et al. 2016. Expression of CD33 is a predictive factor for effect of gemtuzumab ozogamicin at different doses in adult acute myeloid leukaemia. Leukemia 31(5), pp. 1059-1068. (10.1038/leu.2016.309)
- Khan, N.et al. 2016. Normal hematopoietic progenitor subsets have distinct reactive oxygen species, BCl2 and cell-cycle profiles that are decoupled from maturation in acute myeloid leukemia. PLOS ONE 11(9), article number: e0163291. (10.1371/journal.pone.0163291)
- Chilton, L.et al. 2016. The prognostic significance of trisomy 4 in acute myeloid leukaemia is dependent on age and additional abnormalities. Leukemia 30(11), pp. 2264-2267. (10.1038/leu.2016.200)
- Burnett, A. K., Russell, N. H. and Hills, R. K. 2016. Higher daunorubicin exposure benefits FLT3 mutated acute myeloid leukemia. Blood 128(3), pp. 449-452. (10.1182/blood-2016-04-712091)
- Russell, N. H.et al. 2016. Potential benefit of higher dose daunorubicin in patients harbouring a FLT3-ITD mutation: Updated results of the AML17 trial. British Journal of Haematology 173(S1), pp. 9-9.
- Zabkiewicz, J.et al. 2016. The targeted histone deacetylase inhibitor tefinostat (CHR-2845) shows selective in vitro efficacy in monocytoid-lineage leukaemias. Oncotarget 7(13), pp. 16650-16662. (10.18632/oncotarget.7692)
- Ivey, A.et al. 2016. Assessment of minimal residual disease in standard-risk AML. New England Journal of Medicine 374(5), pp. 422-433. (10.1056/NEJMoa1507471)
- Dickson, G. J.et al. 2016. The value of molecular stratification for CEBPA DM and NPM1 MUT FLT3 WT genotypes in older patients with acute myeloid leukaemia. British Journal of Haematology 172(4), pp. 573-580. (10.1111/bjh.13873)
- Burnett, A. K.et al. 2016. Defining the dose of gemtuzumab ozogamicin in combination with induction chemotherapy in acute myeloid leukemia: a comparison of 3 mg/m2 with 6 mg/m2 in the NCRI AML17 trial. Haematologica 101(6), pp. 724-731. (10.3324/haematol.2016.141937)
2015
- Munje, C.et al. 2015. Cord blood-derived quiescent CD34+ cells are more transcriptionally matched to AML blasts than cytokine-induced normal human hematopoietic CD34+ cells. Gene Expression 16(4), pp. 169-175. (10.3727/105221615X14399878166159)
- Howard, R.et al. 2015. Nursing home placement in the donepezil and memantine in moderate to severe Alzheimer's Disease (DOMINO-AD) trial: secondary and post-hoc analyses. The Lancet Neurology 14(12), pp. 1171-1181. (10.1016/S1474-4422(15)00258-6)
- Burnett, A. K.et al. 2015. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. The Lancet Oncology 16(13), pp. 1295-1305. (10.1016/S1470-2045(15)00193-X)
- Tawana, K.et al. 2015. Disease evolution and outcomes in familial AML with germline CEBPA mutations. Blood 126(10), pp. 1214-1223. (10.1182/blood-2015-05-647172)
- Khan, N.et al. 2015. An immunophenotypic pre-treatment predictor for poor response to induction chemotherapy in older acute myeloid leukaemia patients: blood frequency of CD34+ CD38 lowblasts. British Journal of Haematology 170(1), pp. 80-84. (10.1111/bjh.13398)
- Russell, N. H.et al. 2015. A comparative assessment of the curative potential of reduced intensity allografts in acute myeloid leukaemia. Leukemia 29(7), pp. 1478-1484. (10.1038/leu.2014.319)
- Gale, R. E.et al. 2015. Simpson's Paradox and the impact of different DNMT3A mutations on outcome in younger adults with acute myeloid leukemia. Journal of Clinical Oncology 33(18), pp. 2072-2083. (10.1200/JCO.2014.59.2022)
- Simpson, K.et al. 2015. Telomere fusion threshold identifies a poor prognostic subset of breast cancer patients. Molecular Oncology 9(6), pp. 1186-1193. (10.1016/j.molonc.2015.02.003)
- Lazenby, M.et al. 2015. The HSP90 inhibitor ganetespib: A potential effective agent for Acute Myeloid Leukemia in combination with cytarabine. Leukemia Research 39(6), pp. 617-624. (10.1016/j.leukres.2015.03.016)
- Dennis, M.et al. 2015. Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia. Blood 125(19), pp. 2923-2932. (10.1182/blood-2014-10-608117)
- Kuhnl, A.et al. 2015. Downregulation of the Wnt inhibitor CXXC5 predicts a better prognosis in acute myeloid leukemia. Blood 125(19), pp. 2985-2994. (10.1182/blood-2014-12-613703)
- Burnett, A. K.et al. 2015. A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients. Blood 125(25), pp. 3878-3885. (10.1182/blood-2015-01-623447)
- Walter, R. B.et al. 2015. Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center. Leukemia 29(2), pp. 312-320. (10.1038/leu.2014.242)
- Scurr, M. J.et al. 2015. Assessing the prognostic value of preoperative carcinoembryonic antigen-specific T-cell responses in colorectal cancer. JNCI Journal of the National Cancer Institute 107(4), article number: djv001. (10.1093/jnci/djv001)
2014
- Hills, R. K.et al. 2014. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. The Lancet Oncology 15(9), pp. 986-996. (10.1016/S1470-2045(14)70281-5)
- Linch, D. C.et al. 2014. Impact of FLT3ITD mutant allele level on relapse risk in intermediate-risk acute myeloid leukemia. Blood 124(2), pp. 273-276. (10.1182/blood-2014-02-554667)
- Roboz, G. J.et al. 2014. International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia. Journal of Clinical Oncology 32(18), pp. 1919-1926. (10.1200/JCO.2013.52.8562)
- Zabkiewicz, J.et al. 2014. The PDK1 master kinase is over-expressed in acute myeloid leukemia and promotes PKC-mediated survival of leukemic blasts. Haematologica 99(5), pp. 858-864. (10.3324/haematol.2013.096487)
- Mohamed, I., Hills, R. and Burnett, A. K. 2014. Who is an "older" patient with acute myeloid leukaemia (AML)? An investigation of two NCRI/AML trials. British Journal of Haematology 165(1), pp. 147-151. (10.1111/bjh.12705)
- Lin, T. T.et al. 2014. Telomere dysfunction accurately predicts clinical outcome in chronic lymphocytic leukaemia, even in patients with early stage disease. British Journal of Haematology 167(2), pp. 214-223. (10.1111/bjh.13023)
- Grimwade, D., Jovanovic, J. V. and Hills, R. 2014. Can we say farewell to monitoring minimal residual disease in acute promyelocytic leukaemia?. Best Practice & Research Clinical Haematology 27(1), pp. 53-61. (10.1016/j.beha.2014.04.002)
- Lazenby, M.et al. 2014. The prognostic relevance of flt3 and npm1 mutations on older patients treated intensively or non-intensively: a study of 1312 patients in the UK NCRI AML16 trial. Leukemia 28, pp. 1953-1959. (10.1038/leu.2014.90)
- El-Sharkawi, D.et al. 2014. ASXL1 mutations are infrequent in young patients with primary acute myeloid leukemia and their detection has a limited role in therapeutic risk stratification. Leukemia and Lymphoma 55(6), pp. 1326-1331. (10.3109/10428194.2013.833332)
- Chilton, L.et al. 2014. Hyperdiploidy with 49-65 chromosomes represents a heterogeneous cytogenetic subgroup of acute myeloid leukemia with differential outcome. Leukemia 28, pp. 321-328. (10.1038/leu.2013.198)
2013
- Hole, P. S.et al. 2013. Overproduction of NOX-derived ROS in AML promotes proliferation and is associated with defective oxidative stress signaling. Blood 122(19), pp. 3322-3330. (10.1182/blood-2013-04-491944)
- Allen, C.et al. 2013. The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia. Leukemia 27(9), pp. 1891-1901. (10.1038/leu.2013.186)
- Burnett, A. K.et al. 2013. Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the Medical Research Council AML15 trial. Journal of Clinical Oncology 31(27), pp. 3360-3368. (10.1200/JCO.2012.47.4874)
- Burnett, A. K.et al. 2013. Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival. Blood 122(8), pp. 1384-1394. (10.1182/blood-2013-04-496596)
- Senapati, A.et al. 2013. PROSPER: a randomised comparison of surgical treatments for rectal prolapse. Colorectal Disease 15(7), pp. 858-868. (10.1111/codi.12177)
- Green, C. L.et al. 2013. GATA2 mutations in sporadic and familial acute myeloid leukaemia patients with CEBPA mutations. British Journal of Haematology 161(5), pp. 701-705. (10.1111/bjh.12317)
- Pembroke, T.et al. 2013. The paradox of NKp46+ natural killer cells: drivers of severe hepatitis C virus-induced pathology but in-vivo resistance to interferon treatment. Gut n/a (10.1136/gutjnl-2013-304472)
- Burnett, A. K. and Hills, R. K. 2013. No evidence of survival benefit with addition of gemtuzumab ozogamicin to standard Medical Research Council induction chemotherapy - Reply [Letter]. Journal of Clinical Oncology 31(13), pp. 1700-1701. (10.1200/JCO.2013.48.6571)
- Craddock, C.et al. 2013. Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia. Leukemia 27(5), pp. 1028-1036. (10.1038/leu.2012.312)
- Nacheva, E. P.et al. 2013. Does BCR/ABL1 positive acute myeloid leukaemia exist?. British Journal of Haematology 161(4), pp. 541-550. (10.1111/bjh.12301)
- Burnett, A. K.et al. 2013. Curability of patients with acute myeloid leukemia who did not undergo transplantation in first remission. Journal of Clinical Oncology 31(10), pp. 1293-1301. (10.1200/JCO.2011.40.5977)
- Burnett, A. K.et al. 2013. Inclusion of chemotherapy in addition to anthracycline in the treatment of acute promyelocytic leukaemia does not improve outcomes: results of the MRC AML15 trial. Leukemia 27(4), pp. 843-851. (10.1038/leu.2012.360)
- Ling, V.et al. 2013. Utility of a clinical risk score to identify high-risk patients with de novo acute myeloid leukaemia in first remission after high-dose cytarabine (HiDAC) based induction chemotherapy. British Journal of Haematology 160(6), pp. 861-863. (10.1111/bjh.12178)
- McLornan, D.et al. 2013. Prognostic and therapeutic relevance of c-FLIP in acute myeloid leukaemia. British Journal of Haematology 160(2), pp. 188-198. (10.1111/bjh.12108)
- Walter, R. B.et al. 2013. Significance of FAB subclassification of "acute myeloid leukemia, NOS" in the 2008 WHO classification: analysis of 5848 newly diagnosed patients. Blood 121(13), pp. 2424. (10.1182/blood-2012-10-462440)
- Burnett, A. K.et al. 2013. The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison. Leukemia 27, pp. 75-81. (10.1038/leu.2012.229)
2012
- Daud, S. S.et al. 2012. Identification of the Wnt signalling protein, TCF7L2 as a significantly overexpressed transcription factor in AML [Abstract]. Blood 120(21), article number: 1281.
- Bradbury, C. A.et al. 2012. Residual disease detection by flow cytometry predicts risk of relapse and overall survival in patients with Acute Myeloid Leukemia following reduced intensity- and Myeloablative- Allogeneic Hematopoietic Cell Transplantation [Abstract]. Blood -New York- 120(21)
- Russell, N. H.et al. 2012. Reduced intensity transplant may improve survival in patients over the age of 40, especially if a sibling donor Is Used: pooled analysis of 2454 patients and 407 transplants in the UK NCRI AML15 and AML16 trials [Abstract]. Blood -New York- 120(21)
- Burnett, A. K.et al. 2012. A randomised comparison of Clofarabine versus low dose Ara-C as first line treatment for older patients with AML [Abstract]. Blood -New York- 120(21)
- Burnett, A. K.et al. 2012. A comparison of Daunorubicin/Ara-C (DA) versus Daunorubicin/Clofarabine (DClo) and two versus three courses of total treatment for older patients with AML and high risk MDS: results of the UK NCRI AML16 Trial [Abstract]. Blood -New York- 120(21)
- Yin, J. A. L.et al. 2012. Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial. Blood 120(14), pp. 2826-2835. (10.1182/blood-2012-06-435669)
- Burnett, A. K.et al. 2012. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. Journal of Clinical Oncology 30(32), pp. 3924-3931. (10.1200/JCO.2012.42.2964)
- Coles, S.et al. 2012. Expression of CD200 on AML blasts directly suppresses memory T-cell function [Letter]. Leukemia 26(9), pp. 2148-2151. (10.1038/leu.2012.77)
- Coles, S.et al. 2012. Increased CD200 expression in acute myeloid leukemia is linked with an increased frequency of FoxP3+ regulatory T cells [Letter]. Leukemia 26(9), pp. 2146-2148. (10.1038/leu.2012.75)
- Hills, R. K. 2012. The contribution of randomized trials to the cure of haematological disorders from Bradford Hill onwards. British Journal of Haematology 158(6), pp. 691-699. (10.1111/j.1365-2141.2012.09213.x)
- Burnett, A. K.et al. 2012. The addition of the farnesyl transferase inhibitor, tipifarnib, to low dose cytarabine does not improve outcome for older patients with AML. British Journal of Haematology 158(4), pp. 519-522. (10.1111/j.1365-2141.2012.09165.x)
- Burnett, A. K.et al. 2012. The addition of gemtuzumab ozogamicin to induction chemotherapy in AML reduces relapse and improves survival in the majority of patients of all ages: the AML15 and 16 trial experience [Abstract]. British Journal of Haematology 157(S1), pp. 1. (10.1111/j.1365-2141.2012.09071.x)
- El-Sharkawi, D.et al. 2012. ASXL1 mutations are infrequent in young patients with primary acute myeloid leukaemia [Abstract]. British Journal of Haematology 157(S1), pp. 56-56. (10.1111/j.1365-2141.2012.09071.x)
- Allen, C. G.et al. 2012. The impact of mutant level on clinical outcome in acute myeloid leukaemia differs according to the mutated gene [Abstract]. British Journal of Haematology 157(S1), pp. 20. (10.1111/j.1365-2141.2012.09071.x)
- Sunter, N. J.et al. 2012. A functional variant in the core promoter of the CD95 cell death receptor gene predicts prognosis in acute promyelocytic leukemia. Blood 119(1), pp. 196-205. (10.1182/blood-2011-04-349803)
- Pepper, C. J.et al. 2012. Defining the prognosis of early stage chronic lymphocytic leukaemia patients. British Journal of Haematology 156(4), pp. 499-507. (10.1111/j.1365-2141.2011.08974.x)
- Sunter, N. J.et al. 2012. A functional variant in the core promoter of the CD95 cell death receptor gene predicts prognosis in acute promyelocytic leukemia. Blood 119(1), pp. 196-205. (10.1182/blood-2011-04-349803)
- Howard, R.et al. 2012. Donepezil and memantine for moderate-to-severe Alzheimer's Disease. New England Journal of Medicine 366(10), pp. 893-903. (10.1056/NEJMoa1106668)
2011
- Coles, S.et al. 2011. CD200 inhibits memory Th1 cell function in acute myeloid leukaemia (AML)[Abstract]. Immunology 135(S1), pp. 178. (10.1111/j.1365-2567.2011.03534.x)
- Craddock, C. F.et al. 2011. Quantitation of leukemic stem cell populations predicts clinical outcome in Acute Myeloid Leukaemia. Blood -New York- 118(21), pp. 292-292.
- Burnett, A. K.et al. 2011. The addition of Gemtuzumab Ozogamicin to intensive chemotherapy in older patients with AML produces a significant improvement in overall survival: results of the UK NCRI AML16 randomized trial. Blood -New York- 118(21), pp. 268-268.
- Allen, C. G.et al. 2011. Mutations in a large cohort of young adult patients with core binding factor acute myeloid leukemia: Impact on outcome and the selection of patients for alternative treatment including transplantation in first complete remission [Abstract]. Blood 118(21), pp. 193-193.
- Knapper, S.et al. 2011. The efficacy of the FLT3 inhibitor Lestaurtinib in AML depends on adequate plasma inhibitory activity (PIA), and is unaffected by rising FLT ligand levels: an update of the NCRI AML15 & 17 trials. Blood -New York- 118(21), pp. 194-194.
- Mohamedali, A. M.et al. 2011. Single Nucleotide Polymorphism Array (SNP-A) karyotype is the best predictor of prognosis in normal cytogenetics Acute Myeloid Leukaemia (AML). Blood -New York- 118(21), pp. 188-189.
- Hills, R. K. and Burnett, A. K. 2011. Applicability of a "Pick a Winner" trial design to acute myeloid leukemia. Blood 118(9), pp. 2389-2394. (10.1182/blood-2011-02-337261)
- Pallis, M.et al. 2011. Analysis of the interaction of induction regimens with p-glycoprotein expression in patients with acute myeloid leukaemia: results from the MRC AML15 trial. Blood Cancer Journal 1, article number: e23.
- Dojcinov, S. D.et al. 2011. Age-related EBV-associated lymphoproliferative disorders in the Western population: a spectrum of reactive lymphoid hyperplasia and lymphoma. Blood 117(18), pp. 4726-4735. (10.1182/blood-2010-12-323238)
- Burnett, A. K.et al. 2011. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: Results of the MRC AML15 Trial. Journal of Clinical Oncology 29(4), pp. 369-377. (10.1200/JCO.2010.31.4310)
- Coles, S.et al. 2011. CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia. Leukemia 25(5), pp. 792-799. (10.1038/leu.2011.1)
- Daniels, J. P.et al. 2011. Intrapartum tests for group B streptococcus: accuracy and acceptability of screening. BJOG: An International Journal of Obstetrics & Gynaecology 118(2), pp. 257-265. (10.1111/j.1471-0528.2010.02725.x)
- Daniels, J. P.et al. 2011. Intrapartum tests for group B streptococcus: accuracy and acceptability of screening. BJOG-an International Journal of Obstetrics and Gynaecology 118(2), pp. 257-265. (10.1111/j.1471-0528.2010.02725.x)
- Smith, M. L., Hills, R. K. and Grimwade, D. 2011. Independent prognostic variables in acute myeloid leukaemia. Blood Reviews 25(1), pp. 39-51. (10.1016/j.blre.2010.10.002)
- Burnett, A. K. and Hills, R. K. 2011. Who should be transplanted in first remission of Acute Myeloid Leukaemia?. Current Treatment Options in Oncology 12(4), pp. 329-340. (10.1007/s11864-011-0169-x)
- Smith, M. L., Hills, R. K. and Grimwade, D. 2011. Independent prognostic variables in acute myeloid leukaemia. Blood Reviews 25(1), pp. 39-51. (10.1016/j.blre.2010.10.002)
- Majid, A.et al. 2011. CD49d is an independent prognostic marker that is associated with CXCR4 expression in CLL. Leukemia Research 35(6), pp. 750-756. (10.1016/j.leukres.2010.10.022)
- Burnett, A. K.et al. 2011. The addition of arsenic trioxide to low-dose Ara-C in older patients with AML does not improve outcome. Leukemia 25(7), pp. 1122-1127. (10.1038/leu.2011.59)
- Green, C.et al. 2011. The prognostic significance of IDH2 mutations in AML depends on the location of the mutation. Blood 118(2), pp. 409-412. (10.1182/blood-2010-12-322479)
- Dojcinov, S. D.et al. 2011. Age-related EBV-associated lymphoproliferative disorders in the Western population: a spectrum of reactive lymphoid hyperplasia and lymphoma. Blood 117(18), pp. 4726-4735. (10.1182/blood-2010-12-323238)
2010
- Bajuaifer, N.et al. 2010. A polymorphism in the 3'UTR region of ABCB1 is associated with increased allele activity with corresponding increases in P-glycoprotein expression and function [Abstract]. Blood 116(21), pp. 1626.
- Wei, A. H.et al. 2010. A phase Ib study Combining the mTOR inhibitor everolimus (RAD001) with low-dose cytarabine In untreated elderly AML [Abstract]. Blood 116(21), pp. 1351-1352.
- Mohamedali, A.et al. 2010. Prognostic significance of cryptic genomic aberrations in AML with normal karyotype [Abstract]. Blood 116(21), pp. 1125.
- Pallis, M.et al. 2010. Analysis of the interaction of induction regimens with P-glycoprotein expression in patients with acute myeloid leukaemia: results from the MRC AML15 Trial [Abstract]. Blood 116(21), pp. 1123.
- Sunter, N. J.et al. 2010. A functional polymorphism in the CD95 cell death receptor associated with prognosis in acute promyelocytic leukemia [Abstract]. Blood 116(21), article number: 756.
- Freeman, S.et al. 2010. Detection of immunophenotypic residual disease after induction therapy is an independent prognostic factor for duration of remission in older AML patients treated intensively [Abstract]. Blood 116(21), pp. 1118-1119.
- Zabkiewicz, J.et al. 2010. PDK1 overexpression in acute myeloid leukemia; Clinical significance and potential as a therapeutic target [Abstract]. Blood 116(21), pp. 892-893.
- Morgan, R. G.et al. 2010. Distinct regulation of beta- and gamma-Catenin throughout hematopoietic development contrasts with their cooperative roles in acute myeloid leukemia [Abstract]. Blood 116(21), article number: 1573.
- Daniels, J. P.et al. 2010. Individual patient data meta-analysis of randomized evidence to assess the effectiveness of laparoscopic uterosacral nerve ablation in chronic pelvic pain. Human Reproduction Update 16(6), pp. 568-576. (10.1093/humupd/dmq031)
- Stringaris, K.et al. 2010. A distinct signature of natural killer cell KIR gene frequencies in secondary AML compared with de novo AML and normal controls. Blood 116(21), pp. 711-712.
- Coles, S.et al. 2010. Over-expression of CD200 un acute myeloid leukemia mediates the expansion of regulatory T-lymphocytes and directly inhibits natural killer cell tumor immunity [Abstract]. Blood 116(21), pp. 218-218.
- Green, C. L.et al. 2010. Younger adult acute myeloid leukemia (AML) patients with IDH2-R140 mutations have a significantly better prognosis than those with either IDH2-R172 or IDH1 mutations [Abstract]. Blood 116(21), pp. 50.
- Green, C. L.et al. 2010. The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status. Blood 116(15), pp. 2779-2782. (10.1182/blood-2010-02-270926)
- Grimwade, D.et al. 2010. Refinement of cytogenetic classification in acute myeloid leukemia: Determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 116(3), pp. 354-365. (10.1182/blood-2009-11-254441)
- Grimwade, D.et al. 2010. Refinement of cytogenetic classification in acute myeloid leukaemia: Determination of prognostic significance of rarer recurring chromosomal abnormalities amongst 5,876 younger adult patients treated in the UK Medical Research Council trials [Abstract]. British Journal of Haematology 149(S1), pp. 17. (10.1111/j.1365-2141.2010.08116.x)
- Liddiard, K.et al. 2010. OGG1 is a novel prognostic indicator in acute myeloid leukaemia. Oncogene 29(13), pp. 2005-2012. (10.1038/onc.2009.462)
- Bick, D. E.et al. 2010. PErineal Assessment and Repair Longitudinal Study (PEARLS): protocol for a matched pair cluster trial. BMC Pregnancy and Childbirth 10, article number: 10.
- Burnett, A. K.et al. 2010. The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA. Blood 115(5), pp. 948-956. (10.1182/blood-2009-08-236588)
- Grimwade, D.et al. 2010. How should we prevent hematologic relapse of acute promyelocytic leukemia? Reply [Letter]. Journal of Clinical Oncology 28(4), pp. E63-E64. (10.1200/JCO.2009.24.9995)
- Burnett, A. K.et al. 2010. Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial. Journal of Clinical Oncology 28(4), pp. 586-595. (10.1200/JCO.2009.22.9088)
- Green, C. L.et al. 2010. The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukaemia is dependent on FLT3/ITD status [Abstract]. British Journal of Haematology 149(S1), pp. 17. (10.1111/j.1365-2141.2010.08116.x)
- Daniels, J. P.et al. 2010. Individual patient data meta-analysis of randomized evidence to assess the effectiveness of laparoscopic uterosacral nerve ablation in chronic pelvic pain. Human Reproduction Update 16(6), pp. 568-576. (10.1093/humupd/dmq031)
- Burnett, A. K.et al. 2010. The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA. Blood 115(5), pp. 948-956. (10.1182/blood-2009-08-236588)
- Green, C. L.et al. 2010. The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status. Blood 116(15), pp. 2779-2782. (10.1182/blood-2010-02-270926)
- Harrison, C. J.et al. 2010. Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council treatment trials AML 10 and 12. Journal of Clinical Oncology 28(16), pp. 2674-2681. (10.1200/JCO.2009.24.8997)
- Green, C.et al. 2010. Prognostic Significance of CEBPA Mutations in a Large Cohort of Younger Adult Patients With Acute Myeloid Leukemia: Impact of Double CEBPA Mutations and the Interaction With FLT3 and NPM1 Mutations. Journal of Clinical Oncology 28(16), pp. 2739-2747. (10.1200/JCO.2009.26.2501)
2009
- Cilloni, D.et al. 2009. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study. Journal of Clinical Oncology 27(31), pp. 5195-5201. (10.1200/JCO.2009.22.4865)
- Burnett, A. K.et al. 2009. Attempts to optimise induction and consolidation chemotherapy in patients with Acute Myeloid Leukaemia: results of the MRC AML15 trial.. Blood -New York- 114(22), pp. 200-200.
- Knapper, S.et al. 2009. Lestaurtinib FLT3 inhibitory activity is modulated by concomitant azole therapy and may Influence relapse risk. Blood -New York- 114(22), pp. 326-326.
- Russell, N. H.et al. 2009. Low dose Ara-C versus low dose Ara-C and arsenic trioxide: The UK NCRI AML16 "Pick a Winner" comparison [Abstract]. Blood 114(22), pp. 201-201.
- Russell, N. H.et al. 2009. Outcome of reduced intensity allografts in patients aged over 45 years with Acute Myeloid Leukaemia: initial results of the MRC AML15 trial. Blood -New York- 114(22), pp. 217-217.
- Grimwade, D.et al. 2009. Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. Journal of Clinical Oncology 27(22), pp. 3650-3658. (10.1200/JCO.2008.20.1533)
- McLornan, P.et al. 2009. The prognostic role of C-Flip in AML [Abstract]. Haematologica 94(S2), pp. 108.
- Burnett, A. K.et al. 2009. The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial. British Journal of Haematology 145(3), pp. 318-332. (10.1111/j.1365-2141.2009.07604.x)
- Hewamana, S.et al. 2009. Rel A is an independent biomarker of clinical outcome in chronic lymphocytic leukemia. Journal of Clinical Oncology 27(5), pp. 763-769. (10.1200/JCO.2008.19.1114)
- Daniels, J.et al. 2009. Laparoscopic uterosacral nerve ablation for alleviating chronic pelvic pain: a randomized controlled trial. JAMA - The Journal of the American Medical Association 302(9), pp. 955-961. (10.1001/jama.2009.1268)
- Fitzgibbon, J.et al. 2009. In Reply [to 'Comparing Apples and Oranges in Normal Karyotype Acute Myeloid Leukemia' by Bruno C. Medeiros] [Letter]. Journal of Clinical Oncology 27(3), pp. 474-476. (10.1200/JCO.2008.19.4894)
- Grimwade, D.et al. 2009. Reply to S. Nagai et al [Letter]. Journal of Clinical Oncology 28(4), pp. e63-e64. (10.1200/JCO.2009.25.0522)
- Daniels, J.et al. 2009. Rapid testing for group B streptococcus during labour: a test accuracy study with evaluation of acceptability and cost-effectiveness. Health Technology Assessment 13(42), pp. 1-178. (10.3310/hta13420)
- Hills, R. K., Gray, R. and Wheatley, K. 2009. Balancing treatment allocations by clinician or center in randomized trials allows unacceptable levels of treatment prediction. Journal of Evidence-Based Medicine 2(3), pp. 196-204. (10.1111/j.1756-5391.2009.01023.x)
2008
- Pepper, C. J.et al. 2008. Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers. Blood 112(9), pp. 3807-3817. (10.1182/blood-2008-05-157131)
- Mansour, M. . R.et al. 2008. CSL-TREX: A novel alternatively spliced isoform of CSL (RBPJ-K) predominates over the full-length isoform in many patients with acute myeloid leukaemia can activate notch signalling and is associated with improved outcome [Abstract]. Blood 112(11), pp. 1155-1155.
- Virappane, P.et al. 2008. Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: The United Kingdom Medical Research Council Adult Leukaemia Working Party. Journal of Clinical Oncology 26(33), pp. 5429-5435. (10.1200/JCO.2008.16.0333)
- Burnett, A. K.et al. 2008. Low dose Ara-C versus low Dose Ara-C and Tipifarnib: result of the UK NCRI AML16 "Pick a Winner" comparison [Abstract]. Blood -New York- 112(11), pp. 1017-1018.
- Hills, R. K.et al. 2008. A retrospective comparison of matched elderly patients treated with Laromustine (Cloretazine (R)) or Best Supportive Care or Low Dose Ara-C in the LRF AML14 Trial [Abstract]. Blood 112(11), pp. 1017.
- Gale, R.et al. 2008. The impact of FLT3-ITD and NPM1 Mutational Status on the outcome of ATRA therapy in patients with Non-APL AML: results of the UK MRC AML12 trial [Abstract]. Blood -New York- 112(11), pp. 207-207.
- Liu-Yin, J. A.et al. 2008. Predictive value of Minimal Residual Disease (MRD) monitoring by RQ-PCR in WT1 positive patients entered in the UK MRC AML-15 trial. Blood -New York- 112(11), pp. 259-260.
- Cilloni, D.et al. 2008. Early assessment of minimal residual disease (MRD) by optimized real-time quantitative PCR (RQ-PCR) assay for detection of WTL transcripts provides an independent predictor of disease relapse in Acute Myeloid Leukemia: a European Leukemianet (ELN) Study. Haematologica 93, pp. 169-169.
- Grimwade, D.et al. 2008. Evaluation of prospective real-time quantitative PCR monitoring for minimal residual disease to predict relapse and direct molecularly targeted therapy with arsenic trioxide in acute promyelocytic leukaemia: analysis of 407 patients, including results of the MRC AML15 trial [Abstract]. British Journal of Haematology 141(S1), pp. 59.
- Bowen, D.et al. 2008. TP53 gene mutation is frequent in patients with acute myeloid leukemia and complex karyotype, and is associated with very poor prognosis [Letter]. Leukemia 23(1), pp. 203-206. (10.1038/leu.2008.173)
- Gale, R. E.et al. 2008. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood 111(5), pp. 2776-2784. (10.1182/blood-2007-08-109090)
- Mead, A. J.et al. 2008. Conflicting data on the prognostic significance of FLT3/TKD mutations in acute myeloid leukemia might be related to the incidence of biallelic disease [Letter]. Blood 112(2), pp. 444-445. (10.1182/blood-2008-02-140392)
- Hills, R. K. 2008. Research in cancer. In: Hanna, L., Crosby, T. and Macbeth, F. eds. Practical clinical oncology.. Cambridge: Cambridge University Press, pp. 55-69.
- Guy, C.et al. 2008. The impact of MN1 over-expression on the outcome of younger patients with AML treated with intensive chemotherapy with or without ATRA therapy [Abstract]. Blood -New York- 112(11), pp. 1023-1023.
2007
- Gray, R.et al. 2007. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 370(9604), pp. 2020-2029. (10.1016/S0140-6736(07)61866-2)
- Bentham, P.et al. 2007. Aspirin in Alzheimer's disease (AD2000): a randomised open-label trial. The Lancet Neurology 7(1), pp. 41-49.
- Burnett, A. K.et al. 2007. Idarubicin and ATRA is as effective as MRC chemotherapy in patients with acute promyelocytic leukaemia with lower toxicity and resource usage: Preliminary results of the MRC AML15 trial. Blood -New York- 110(11), pp. 181A-181A.
- Cilloni, D.et al. 2007. Real-time quantitative PCR (RQ-PCR) detection of minimal residual disease (MRD) by optimized WT1 assay to enhance risk stratification in acute myeloid leukemia (AML): A European leukemia net study [Abstract]. Blood 110(11), pp. 167A.
- Yin, J. A. L.et al. 2007. Minimal residual disease monitoring by RQ-PCR in core binding factor positive AML allows risk-stratification and predicts relapse: Results of the UK MRC AML-15 trial.. Blood 110(11), pp. 167A.
- Young, A.et al. 2007. Meta-analysis of randomised comparisons between the effects of warfarin and low molecular weight heparin in thromboprophylaxis and mortality in cancer patients [Abstract]. EJC Supplements 5(4), pp. 142.
- Mead, A. J.et al. 2007. FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia. Blood 110(4), pp. 1262-1270. (10.1182/blood-2006-04-015826)
- Virappane, P.et al. 2007. Wilms' tumour 1 mutation in normal karyotype aml. Haematologica 92(S1), pp. 19-20.
- Grimwade, D.et al. 2007. Use of quantitative PCR approaches to predict relapse and direct molecularly targeted therapy with arsenic trioxide (ATO) in acute promyelocytic leukaemia (APL)[Abstract]. British Journal of Haematology 137(S1), pp. 39. (10.1111/j.1365-2141.2007.06557.x)
- Burnett, A. K.et al. 2007. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer 109(6), pp. 1114-1124. (10.1002/cncr.22496)
- Tonks, A.et al. 2007. CD200 as a prognostic factor in acute myeloid leukaemia. Leukemia 21(3), pp. 566-568. (10.1038/sj.leu.2404559)
- Tonks, A.et al. 2007. CD200 as a prognostic factor in acute myeloid leukaemia [Letter]. Leukemia 21(3), pp. 566-568. (10.1038/sj.leu.2404559)
- Kettle, C., Hills, R. K. and Ismail, K. M. K. 2007. Continuous versus interrupted sutures for repair of episiotomy or second degree tears. Cochrane Database of Systematic Reviews 17(4) (10.1002/14651858.CD000947.pub2)
2006
- Wheatley, K., Hills, R. K. and Burnett, A. K. 2006. Problems with up-front randomization in clinical trials. Journal of Clinical Oncology 24(34), pp. 5471-5472. (10.1200/JCO.2006.08.3048)
- Hills, R. K., Kell, W. J. and Burnett, A. K. 2006. Treatment of AML in the elderly: Who is "Fit" for intensive chemotherapy?. Blood -New York- 108(11), pp. 559A-559A.
- Burnett, A. K.et al. 2006. The feasibility of combining daunorubicin, clofarabine and gemtuzumab ozogamicin ts feasible and effective. A pilot study.. Blood -New York- 108(11), pp. 551A-552A.
- Grimwade, D.et al. 2006. Real-time detection of PML-RARA and RARA-PML fusion transcripts in high risk acute promyelocytic leukemia (APL) treated with arsenic trioxide (ATO): Implications for realization of pre-emptive therapy for molecular relapse.. Blood -New York- 108(11), pp. 149A-150A.
- Burnett, A. K.et al. 2006. A phase II study (Biov-121) of clofarabine monotherapy first line in patients aged 65 years or older with acute myeloid leukemia for whom standard intensive chemotherapy is not considered suitable.. Blood -New York- 108(11), pp. 130A-130A.
- Burnett, A. K.et al. 2006. A sensitive risk score for directing treatment in younger patients with AML.. Blood -New York- 108(11), pp. 10A-10A.
- Burnett, A. K.et al. 2006. The addition of gemtuzumab ozogamicin to induction chemotherapy for AML improves disease free survival without extra toxicity: Preliminary analysis of 1115 patients in the MRC AML15 trial.. Blood -New York- 108(11), pp. 8A-8A.
- Hills, R. K. and Daniels, J. 2006. Assessing new interventions in women's health. Best Practice & Research Clinical Obstetrics & Gynaecology 20(5), pp. 713-728.
- Wallace, L. M.et al. 2006. A randomised-controlled trial in England of a postnatal midwifery intervention on breast-feeding duration. Midwifery 22(3), pp. 262-273.
- Jordanides, N. E.et al. 2006. hTERT expression in AML is heterogeneous and is of likely prognostic significance. British Journal of Haematology 133(S1), pp. 63-63. (10.1111/j.1365-2141.2006.06027.x)
- Rao, A.et al. 2006. Treatment for myeloid leukaemia of Down syndrome: population-based experience in the UK and results from the Medical Research Council AML 10 and AML 12 trials. British Journal of Haematology 132(5), pp. 576-583. (10.1111/j.1365-2141.2005.05906.x)
2005
- Abe, O.et al. 2005. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. The Lancet 366(9503), pp. 2087-2106.
- Gibson, B. E. S.et al. 2005. Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials. Leukemia 19(12), pp. 2130-2138. (10.1038/sj.leu.2403924)
- Wheatley, K.et al. 2005. Prognostic factors in older AML patients receiving intensive and non-intensive therapy: Analysis of the UK AML11 and AML14 trials [Abstract]. Blood 106(11), pp. 199A.
- Mead, A.et al. 2005. Favourable prognosis associated with FLT3 tyrosine kinase domain mutations in AML in contrast to the adverse outcome associated with internal tandem duplications [Abstract]. Blood 106(11), article number: 334.
- Gale, R. E.et al. 2005. No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials. Blood 106(10), pp. 3658-65. (10.1182/blood-2005-03-1323)
- Wheatley, K.et al. 2005. Meta-analyses of randomised controlled trials (RCT) of warfarin and low molecular weight heparin (LMWH) for the prevention of venous thromboembolism (VTE) and death in cancer patients. Blood -New York- 106(11), pp. 267A-267A.
- Bowen, D. T.et al. 2005. RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years. Blood 106(6), pp. 2113-2119. (10.1182/blood-2005-03-0867)
- al-Jurf, M.et al. 2005. Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. Journal of Clinical Oncology 23(22), pp. 5074-5087. (10.1200/JCO.2005.09.020)
- Hayden, R. E.et al. 2005. NM23-H1 acts as a potent survival factor against primary AML cells and normal blast cells [Abstract]. Experimental Hematology 33(7/S1), pp. 40.
- Abe, O.et al. 2005. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472), pp. 1687-1717.
- Latthe, P. M.et al. 2005. Measurement of beliefs about effectiveness of laparoscopic uterosacral nerve ablation. BJOG-An International Journal of Obstetrics and Gynaecology 112(2), pp. 243-246. (10.1111/j.1471-0528.2004.00304.x)
- Gale, R. E.et al. 2005. Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia. Blood 106(12), pp. 3768-3776. (10.1182/blood-2005-04-1746)
2004
- Allan, J. M.et al. 2004. Genetic variation in XPD predicts treatment outcome and risk of acute myeloid leukemia following chemotherapy. Blood 104(13), pp. 3872-3877. (10.1182/blood-2004-06-2161)
- Allan, J. M.et al. 2004. Genetic variation in XPD predicts treatment outcome and risk of acute myeloid leukemia following chemotherapy. Blood 104(13), pp. 3872-3877. (10.1182/blood-2004-06-2161)
- Burnett, A. K.et al. 2004. The impact of transplant in AML in 2nd CR: A prospective study of 741 in the MRC AML 10 and 12 Trials [Abstract]. Blood 104(11), article number: 179A.
- Burnett, A. K.et al. 2004. Does all-transretinoic acid (ATRA) have a role in non-APL acute myeloid leukaemia?: Results from 1666 patients in three MRC trials [Abstract]. Blood 104(11), article number: 1794.
- Kumar, A.et al. 2004. Experimental vs control interventions in cancer therapy: Which is better? - The Children's Oncology Group experience.. Journal of Clinical Oncology 22(14), pp. 523S-523S.
2003
- Hills, R., Richards, S. M. and Wheatley, K. 2003. Corner cutting compromises clinical trials: the inherent problems with up-front randomisation and a common standard arm. Leukemia Research 27(12), pp. 1071-1073. (10.1016/S0145-2126(03)00126-7)
- Burnett, A. K., Hills, R. K. and Wheatley, K. 2003. Does centre size influence outcome in the treatment of AML in adult patients under 60 years? The MRC AML trial experience [Abstract]. Blood 102(11), pp. 616A-617A.
- Burnett, A. K.et al. 2003. Attempts to modulate chemoresistance in older patients with AML using PSC-833 - Results of the LRF AML14 trial. Blood 102(11), pp. 614A.
- Luong, Q. T.et al. 2003. Expression of Nm23-H1 in AML correlates with white cell count at diagnosis and in vitro acts as a survival factor for primary AMLs cells; evidence of a novel autocrine survival factor in AML.. Blood -New York- 102(11), pp. 611A-611A.
- Harrison, C. J.et al. 2003. Cytogenetics of childhood Acute Myeloid Leukemia: United Kingdom Medical Research Council treatment trials AML 10 and 12. Blood -New York- 102(11), pp. 98A-98A.
- Jan, S., Hills, R. K. and Gray, R. 2003. PROSPER: A uniquely flexible randomised controlled trial in rectal prolapse repair. Controlled Clinical Trials 24(S3), pp. 107S.
- Stowe, R. L.et al. 2003. Surgery for Parkinson's disease: lack of reliable clinical trial evidence. Journal of Neurology, Neurosurgery & Psychiatry 74(4), pp. 519-521. (10.1136/jnnp.74.4.519)
2002
- Kettle, C.et al. 2002. Continuous versus interrupted perineal repair with standard or rapidly absorbed sutures after spontaneous vaginal birth: a randomised controlled trial. The Lancet 359(9325), pp. 2217-2223.
- Wheatley, K.et al. 2002. Evaluating drug treatments for Parkinson's disease: how good are the trials?. British Medical Journal 324(7352), pp. 1508-1511.
2001
- Wheatley, K. and Hills, R. K. 2001. Inappropriate reporting and interpretation of subgroups in the AML-BFM 93 study [Letter]. Leukemia 15(11), pp. 1803-1804.
- Gray, R.et al. 2001. Adjuvant radiotherapy for rectal cancer: a systematic overview of 8,507 patients from 22 randomised trials. The Lancet 358(9290), pp. 1291-1304. (10.1016/S0140-6736(01)06409-1)
- Benedict, K. A. and Hills, R. K. 2001. Magnetoroton scattering by phonons in fractional quantum Hall liquids. Physical Review-B 63(23), article number: 235304. (10.1103/PhysRevB.63.235304)
- Tomlinson, J. W.et al. 2001. Association between premature mortality and hypopituitarism. Lancet 357(9254), pp. 425-431. (10.1016/S0140-6736(00)04006-X)
2000
- Gray, R. G.et al. 2000. Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial. The Lancet 355(9215), pp. 1588-1596. (10.1016/S0140-6736(00)02214-5)
1999
- Benedict, K. A., Hills, R. K. and Mellor, C. J. 1999. Theory of phonon spectroscopy in the fractional quantum Hall regime. Physical Review B 60(15), pp. 10984-10996.
I share responsibility for coordinating numeracy content within the undergraduate medical curriculum, and teach a number of short courses and workshops within the curriculum.
My research groups into several main groups:
1. Acute Myeloid Leukaemia. I am responsible for the statistical design of the NCRI AML trials (the largest in the world), and for analysis of their findings. These trials have grown more complex over the years to keep pace with the fact that AML is no longer seen as a single homogeneous entity, and to embrace new techniques such as molecular monitoring. I additionally perform meta-analyses of therapies, such as gemtuzumab ozogamicin
2. Translational medicine. Translational medicine links the laboratory to the clinic and vice versa. The samples collected from the NCRI AML trials drive basic research which can then identify targets and therapies to be tested in the next generation of trials. Newer, more sophisitcated ways of measuring residual disease are in some cases superseding older prognostic stratifications as seen in the results of AML17 where a partoculalry poor risk group of NPM1 mutant patients could be identified. The trials evaluate these new translational technologies, as in the monitor vs no monitor randomisation, and the MRD-guided therapy in AML18.
3. Methodology. With the move towards personalsied medicine, trial design needs to evolve. I am involved in pan-European approaches to deal with the increasingly fragmented nature of AML with a number of genetically distinct subtypes.